



Fisher & Paykel

HEALTHCARE

Presentation to
UBS Warburg Healthcare Conference
Sydney, Australia
17 October 2002

Fisher & Paykel
HEALTHCARE



Forward Looking Statements

This presentation may include forward-looking statements and actual results could vary. Such forward-looking statements, including statements regarding our future revenue and earnings projections and the development of new markets for our products, are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied in the forward looking statements. For a discussion of factors that could cause actual results to vary from any forward-looking statements, please see our Annual Report on form 20-F, especially Risk Factors.



Investment Highlights


- Leading player in heated humidification devices and consumables for a variety of respiratory markets
- Estimated US\$1 billion+ market opportunity
- High level of innovation
- Global presence
- Competitive NZ cost base
- Strong financial performance
- Experienced management team

NZSE:FPH, NASDAQ:FPHC, ASX:FPH

Markets and Products


- Respiratory humidification
 - Obstructive sleep apnea
 - Neonatal and other
- »»» Consumable products represent approx. 45% of sales

* 12 months to 31 March 2002



Respiratory Humidification

- Normal airway humidification is bypassed or compromised during ventilation or O₂ therapy
- Mucociliary transport system operates less effectively
 - increases risk of infection
 - impairs gas exchange
- Need to deliver gas at physiologically normal levels
 - 37°C body core temperature
 - 44mg/L 100% saturated





Market Opportunity

Humidification systems are utilized to create, control and deliver optimal levels of humidity

- Estimated US\$300+ million market worldwide
 - heated humidifier controllers
 - humidifier chambers
 - breathing circuits
 - unheated humidifiers
 - oxygen therapy supplies
- » Heated humidifiers utilized as systems - creates ongoing consumables revenue stream

Fisher & Paykel's Humidification Systems

Fisher & Paykel has a full range of industry-leading respiratory humidification systems

Products include:

MR850 Respiratory Humidification System

- invasive ventilation, O₂ therapy and non-invasive ventilation
- patented flow measuring technology
- integrated system
- “set and forget” optimal humidity

MR410 Respiratory Humidifier

- O₂ therapy and non-invasive ventilation
- electronic thermostat
- simple controls



Fisher & Paykel
HEALTHCARE

Single-use Components

- Single-use chambers
 - patented auto filling MR290
 - manual filling models
 - Single-use breathing circuits
 - adult and neonatal
 - patented spiral heater wire
 - less condensation
 - delivery of optimal humidity
- »»» On average, 35 system set-ups used per controller per year





Competitive Advantage

- Creating, controlling and delivering optimal humidity poses technical challenges
- Integrated humidifier, chamber, circuit system provides:
 - optimal performance
 - marketing advantage
- Bundled consumable sales driven by installed controllers
 - Estimate F&P has >50% global controller market share
- High level of R&D commitment
- Extensive intellectual property


Respiratory Humidification FY03 Q1

- Revenue growth (USD) +4% on pcp
- Good growth in North America +9%
- Reduced humidifier sales to OEMs and to Europe
- Strong growth in adult breathing circuits +20%
- Neonatal circuits complete MR850 system



Obstructive Sleep Apnea

- Temporary closure of airway during sleep
- Can greatly impair quality of sleep, leading to fatigue; also associated with stroke and heart attack
- Estimated US\$600+ million worldwide market, growing 15%-20%
- 12 million affected by OSA in US alone
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 - key issue with CPAP is compliance
- Humidification provides significant acceptance and compliance improvements



Normal breathing



Patient with OSA

Fisher & Paykel's CPAP Systems

Fisher & Paykel has a broad range of CPAP products, including flow generators, humidifiers and masks

Products include:

HC150 Humidifier

- suitable for use with most OSA flow generators
- patented ambient tracking system



HC220/HC221 Integrated Flow-Generator Humidifier

- compact, integrated unit
- patented ambient tracking system
- compliance optimizer
- proprietary motor technology



Fisher & Paykel
HEALTHCARE

Mask Systems

- Aclaim2 Nasal Mask
 - proprietary sliding attachment
 - bias flow diffuser
 - »»» less leaks, greater comfort
- Oracle™ Oral Mask
 - proprietary oral interface
 - no headgear required





Competitive Advantage

- ▶▶▶ Fisher & Paykel is the pioneer of heated humidification technologies in OSA
- Leveraging heated humidification expertise into rapidly growing market
 - increased penetration of heated humidification in OSA, increased reimbursement
- Benefits of integrated flow-generator humidifier
- Recently-introduced innovative masks

CPAP/Obstructive Sleep Apnea FY03 Q1

- Revenue growth (USD) +18% on pcp
- Increasing acceptance of humidification benefits
- Improved Medicare reimbursement from 1 July 02
- Price reductions less significant
- 45% volume growth in integrated flow-generator humidifiers
- Flow-generator revenue greater than humidifier revenue
- Masks increasing in importance



Fisher & Paykel
HEALTHCARE

Neonatal Warmers and CPAP

- Radiant Warmers
 - 400,000 pre-term live births per year in US
 - warmers required in delivery and NICU
 - precise and stable temperature control
- Infant CPAP System
 - proprietary bubble CPAP, non-invasive, oscillating pressure
 - lower risk alternative to ventilation



Neonatal and warming FY03 Q1

- Revenue growth (USD) +23% on pcp
- Good growth in North America
- Tender driven, lumpy
- Neonatal CPAP in Australasia






Research & Development

- 120 engineers, scientists, physiologists
- Competitive NZ cost base
- Integrated product teams
- Rapid prototype development
- Active clinical research program
- 29 US patents, 25 pending *
- NZ\$3.6M funding over 4 yrs for COPD research

* at 31 Mar 2002

Global Presence




- Direct
 - hospitals, alternate site, home care dealers
 - sales offices in USA/Canada, UK/Ireland, France/Benelux, Germany/Austria, Australia and NZ
- Distributors
 - 100 distributors worldwide - 90 countries
- Original Equipment Manufacturers
 - supply most leading ventilator and CPAP manufacturers



Growth drivers

- Maintain high level of innovation
 - continue to improve existing product lines
 - develop complementary product offerings
- Target new medical applications
 - e.g. COPD
- Increase our international presence

Revenue Growth USD




* Other includes distributed and discontinued products

Operating Results

Three months ending 30 June 02

Margins





Foreign Currency

- Policy: mix of options and contracts
 - 100% year 1, 75% years 2 and 3, options only up to 25% years 4 and 5.
- US\$ represents 80% of NZ export value
- Q1 portfolio (USD):
 - Year 1 100%)
 - Year 2 and 3 75%) average 0.4590 NZD:USD
 - Year 4 and 5 25%)



Fisher & Paykel

HEALTHCARE

Fisher & Paykel
HEALTHCARE